A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Amy Pikalek
UNITY
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema
PEP
Patient Experience and Preference (PEP) Study in nAMD and DME
Teaming Up for Gene Therapy
*This article originally appeared in the McPherson Eye Research Institute Summer 2021 InSights Newsletter Millions of Americans currently battle inherited visual disorders, armed with very few therapeutic options. Recent advances in genome editing, which many believe …
AAO Minority Ophthalmology Mentoring Program Recognizes Efforts at UW
The American Academy of Ophthalmology (AAO) Minority Ophthalmology Mentoring (MOM) program recently released its 2020 Annual Report. The University of Wisconsin Department of Ophthalmology and Visual Sciences was noted as one of 15 programs that …
Licensed to Lead: Faculty Discuss Physician Burnout and Scribes on Podcast
Barbara Blodi, MD, Matthew D. Davis Professor, medical director of the Fundus Photograph Reading Center and retina specialist, and Mark Lucarelli, MD, FACS, were invited to the Licensed to Lead Podcast for a conversation on …
Low Vision Clinic to Offer Expanded Services
Despite the ongoing challenges presented by the COVID-19 pandemic, the UW Health Low Vision Clinic – led by Sanbrita Mondal, OD, clinical adjunct assistant professor – has announced that it will offer expanded services and …
MAC TEL
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (Mac Tel)
BIM2
To identify whether genetic variation or polymorphism in genes that impact angiogenesis can be identified as biomarkers for responsiveness to anti-VEGF therapy in patients with neovascular age-related macular degeneration.